30 results about "Acquired Immuno-Deficiency Syndrome" patented technology

The invention relates to an oral Chinese medicine liquid for treating AIDS, and is characterized in that the medicine combination, composed of centipede, greater celandine, garter snake, pangolin, stiff silkworm, scorpion, house lizard, earthworm, safflower, salvia miltiorrhiza, angelica, rhizoma gastrodiae, radix astragali, chinese ephedra, coix seed, hemlock parsley, common burreed rhizome, rhizoma zedoariae, tambac, shizandra berry, radix puerariae, Indian bread with hostwood, tuber pinellia, achyranthes, cassia twig, immature bitter orange, airpotato yam, atractylodes rhizome, rhizoma atractylodis, broom cypress fruit, angelica dahurica, pollen and cicada slough and so on, is crushed and added with ten times of liquor for soaking for thirty days; then the medicine liquid can be taken orally so as to achieve the purpose of treating AIDS.

The invention relates to the application of a prunus mume extract, and belongs to the field of biomedicines. The extract is obtained by extracting prunus mume with organic solvent, performing liquid extraction with organic solvent, and optionally refining; and can be used for preparing anti-HIV and antibacterial drugs. The inventive drugs have the advantages of high bioavailability of plant, good therapeutic effect, easily accessible raw material, and good safety. Researches and developments on the pharmacological activity of the extract are of great significance, and the extract has wide application prospect.

The invention belongs to the laboratory medicine technology field, which relates to a device and a method of utilizing saliva to execute clinical or non-clinical detecting HIV/AIDS virus. The device of utilizing saliva to execute clinical or non-clinical detecting HIV/AIDS virus includes a strip shape test kit, a columned liquid collecting filter, a piston, a sampling cup, a measuring pipette, phosphate buffer reagent and antihuman IgG antibody-gold colloid conjugate reagent. The invention also provides a method of using the device to execute clinical or non-clinical detecting for saliva. Through detecting the saliva sample, the invention can achieve the requirements of accurate, quick, convenient and secure clinical or non-clinical detecting of HIV/AIDS virus.

A method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as acquired immunodeficiency syndrome (AIDS) includes a glycol derivative. More specifically, the glycol derivative includes diethylene glycol dibenzoate.

The invention belongs to the technical field of medicaments and relates to a heterophylla and astragalus mongholicus reinvigorating particle as well as a preparation method and application thereof in preparation of a medicament for treating acquired immune deficiency syndrome. The method comprises the following steps of: removing the impurities of 15 Chinese herbal medicines such as heterophylla, astragalus mongholicus, radix ophiopogonis, unprocessed rehmannia root, aspartame, angelica, ligustrum lucidum, wolfberry fruit, schisandra, yam, roasted atractylodes, roasted hawthorn, roasted malt, roasted medicated leaven and licorice, washing the rhizomatic Chinese herbal medicines with running water, and drying at a low temperature. The heterophylla and astragalus mongholicus reinvigorating particle is effective in treatment, has the effects of improving the clinical symptoms of patients, enhancing the immunity of the bodies of the patients, strengthening the treatment effect of an antiviral medicament and reducing the toxic and side effects of the antiviral medicament, improving the quality of life and survival ability of the patients and inhibiting the spread of AIDS (Acquired Immune Deficiency Syndrome). In addition to the treatment effect, the heterophylla and astragalus mongholicus reinvigorating particle has small toxic and side effects, is low in cost and is convenient to take and carry.

The invention belongs to the field of biological medicine and relates to an anti-HIV infection peptide, in particular to a polypeptide shown by a formula 1 CP_I(L)_D_I (L), its derivatives, its stereoisomers, or its salts free of physiological toxicity. CP in the formula represents a C-terminal polypeptide derived from HIV-1 gp41 and having HIV-1 inhibiting activity, L represents leucine, I represents isoleucine, and D represents aspartic acid. Variable amino acid is added to the carbon terminal of the C-terminal polypeptide having the HIV-1 inhibiting activity to obtain a longer polypeptide, so that the polypeptide has remarkable strengthened antiviral activity. The invention further relates to a drug composition containing the polypeptide shown by the formula 1, its derivatives, its stereoisomers or its salts free of physiological toxicity and application in preparation of drugs for treating or preventing related diseases caused by HIV infection, especially acquired immune deficiency syndrome.

The invention discloses an anti-AIDS virus bullatacin patch for external use, which comprises a backing layer, a drug reservoir and an anti-sticking layer; a cotton medicinal non-woven fabrics with good permeability is used as the backing layer, a polymeric gel (an acrylate pressure-sensitive gel) as an adhesive; the patch comprises the prepared liquid of bullatacin, and a silicone-oil anti-sticking polyester film is functioned as an anti-sticking layer. The patch for external use has the advantages that not only the disadvantage of serious harmful and side effects of the existing oral or intravenous antitumor drug are solved, but also the disadvantage of heavy skin irritation and a certain extend of toxicity of traditional patches for external use are overcome, and the economic cost is reduced.

The invention relates to an acquired immuno deficiency syndrome diagnosing device with an easily-disassembled functional member used for driving additional sample liquid, and belongs to the field of analysis and testing. Using cheap and extremely-easily-processed polydimethylsiloxane (PDMS) to make a substrate of an acquired immuno deficiency syndrome diagnosing microfluidic chip is a technical objective. Key points of the technical scheme are that the substrate is selected from PDMS which has an original ecological surface, a chain-ring-type electromagnetic fixture which is provided with a micro-type ultrasonic transducer sleeves and is located at a place near a terminal end of a sample liquid flow of the microfluidic chip, the sample liquid flow is induced by an ultrasonic wave to flow from a sample inlet end of the chip toward a terminal direction of the chip along a chip pipeline, the interior of the chip pipeline is filled with micron-sized silicon dioxide particle fillers, and functions of the fillers comprise supporting the internal wall of the pipeline, replacing and compensating an originally-hydrophobic pipeline with an aggregation of hydrophilic microfluidic channels, and squeezing and covering the internal-wall surface of the pipeline to reduce contact opportunities of biological macromolecules and the surface of the internal wall.

The invention discloses an oral liquid for resisting AIDS, which is prepared from cimicifuga rhizome, Bupleurum root, anemarrhena rhizome, raw astragalus root, root of ballon flower, Chinese angelica root, Clematis chinensis, white atractylodes rhizome, dried orange peel, schisandra fruit, gen-seng, tortoiseshell, cornus officinalis, tortoise shell, ledebouriella root, rhizoma dioscoreae, lilyturf root, and licorice root.

The invention is related to humulus scandens, particularly the use thereof in preparing drug for preventing and curing acquired immune deficiency syndrome (AIDS). The drug produced from humulus scandens does not need any assistant drug and has the advantages of preventing and curing AIDS, promoting human metabolism, enhancing human immunity, improving the human disease-resistant ability, conveniency and full absorption, both preventing and treating the disease without any toxic and side effect.

HIV infections are treated with sequential treatment regimens comprising a first regimen which is a combination of highly active antiretroviral therapy drugs selected from the group consisting of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors to reduce the HIV levels; and a second treatment regimen which is administered after said HIV levels are reduced or resistance is observed, said second treatment regimen an amount of an HIV entry/fusion inhibitor to form a modified treatment regimen and continuing to administer said modified treatment regimen for a period of from 10 to 30 days.

The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type-1 (HIV-1) and type-2 (HIV-2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which makes them highly susceptible to debilitating and ultimately fatal opportunistic infections. The invention is directed to a novel crystalline form of the RT inhibitor 3-chloro-5-({1-[(4-methyl-5 -oxo-4,5-dihydro-1 H-1,2, 4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethy 1)-1,2-dihydropyridin-3-yl) oxy)benzonitrile used in the treatment HIV infection and AIDS.

The invention discloses a Chinese medicine used for preparing a medicine for treating AIDS, in particular the application of honeysuckle leaves as a medicine for treating AIDS and as health food. The application of the aqueous extract or the alcohol extract of the honeysuckle leaves as the medicine or the food for treating or preventing AIDS has very obvious effect, the aqueous extract or the alcohol extract can increase the food-intake of a patient, enhance the working capacity, and improve the living quality, and has good therapy effect and small side effect. The invention develops a new way for the promotion and the application of the honeysuckle leaves.

The present invention pertains to methods of inactivating human immunodeficiency virus (HIV), both in vitro and in vivo. Such methods also relate to treating HIV-related symptoms and the treatment of acquired immune deficiency syndrome in patients. Methods typically employ administering a composition comprising ammonium chloride such that HIV is inactivated.